Shanghai Fosun Pharmaceutical (02196) subsidiary has initiated Phase I clinical trials for the integrated diagnosis and treatment project SRT-007 in China.

19:27 30/12/2025

Fosun Pharma announced that its controlled subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has recently initiated Phase I clinical trials of the integrated diagnosis and treatment core drug project SRT-007 in China (excluding mainland China, Hong Kong, Macau, and Taiwan), with indications for the diagnosis and treatment of metastatic castration-resistant prostate cancer with PSMA-positive.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has recently initiated Phase I clinical trials for the integrated diagnosis and treatment nuclear medicine project SRT-007 in China (excluding Hong Kong, Macao, and Taiwan). The indication is for the diagnosis and treatment of metastatic castration-resistant prostate cancer with PSMA-positive.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"